Advertisement
U.S. markets open in 3 hours 37 minutes
  • S&P Futures

    5,067.50
    -13.50 (-0.27%)
     
  • Dow Futures

    38,868.00
    -125.00 (-0.32%)
     
  • Nasdaq Futures

    17,873.00
    -42.25 (-0.24%)
     
  • Russell 2000 Futures

    2,046.10
    +2.70 (+0.13%)
     
  • Crude Oil

    78.52
    -0.02 (-0.03%)
     
  • Gold

    2,040.00
    -2.70 (-0.13%)
     
  • Silver

    22.42
    +0.01 (+0.04%)
     
  • EUR/USD

    1.0844
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    4.2740
    0.0000 (0.00%)
     
  • Vix

    14.01
    +0.17 (+1.23%)
     
  • GBP/USD

    1.2660
    +0.0001 (+0.01%)
     
  • USD/JPY

    150.0500
    -0.5830 (-0.39%)
     
  • Bitcoin USD

    62,678.00
    +3,418.31 (+5.77%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,639.72
    +14.74 (+0.19%)
     
  • Nikkei 225

    39,166.19
    -41.84 (-0.11%)
     

Alzheimer's disease psychosis drug clears mid-stage study -Acadia

Dec 20 (Reuters) - Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer's disease met its main goal in a mid-stage study.

The company said the drug, pimavanserin, showed a statistically significant reduction in psychosis, compared with placebo.

The drug has been approved by the US Food and Drug Administration to treat hallucinations and delusions associated with Parkinson's disease psychosis, the company said.

Acadia said the FDA is yet to approve any drug to treat Alzheimer's disease psychosis.

(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)

Advertisement